Companies in #Cardiovascular Disease

Atrium Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeted therapeutics for cardiovascular diseases. Lead program ATR 1072 is being advanced for PRKAG2 syndrome, a rare genetic cardiac condition.

Cyclerion Therapeutics, Inc. is a biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for central nervous system and peripheral diseases, including CYC-126 for treatment-resistant depression and olinciguat for cardiovascular indications. On April 1, 2026 the company announced a definitive all-stock merger agreement with privately-held Korsana Biosciences; the combined company is expected to operate as Korsana Biosciences, trade on Nasdaq under KRSA, and advance KRSA-028, a next-generation shuttled monoclonal antibody targeting amyloid beta for Alzheimer's disease, supported by a concurrent private financing of approximately $380 million. Cyclerion set the close of business on September 4, 2026 as the record date for a contingent-value-right (CVR) distribution to holders in connection with the merger, and the business combination is expected to close September 8, 2026 — with Cyclerion common stock undergoing a 1-for-7 reverse split and a change of name, symbol, and CUSIP.

New York City-based clinical-stage genetic medicine company advancing disease-modifying gene therapies for genetic cardiovascular conditions and genetic conditions of the central nervous system; in September 2026 it agreed to acquire Mantle Therapeutics to add Friedreich ataxia assets.

Clinical-stage biotech developing oral NLRP3 inflammasome inhibitors, led by dapansutrile (OLT1177), which has advanced from discovery into later-stage clinical development across inflammatory and age-related diseases.

Osanni Bio is a San Francisco-based biotechnology company building a pipeline of therapeutics for ophthalmology and cardiology indications. The company raised $190M in 2026 to advance its portfolio of small-molecule and biologic candidates addressing high-prevalence vision and cardiovascular diseases.

Tectonic Therapeutic is a clinical-stage biotechnology company discovering and developing therapeutic proteins and antibodies that modulate G-protein-coupled receptors (GPCRs), focused on cardiovascular and vascular disease. Its lead program, TX45, is a long-acting Fc-relaxin fusion protein in the pivotal APEX Phase 2 trial for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF); a second program, TX2100, is in Phase 1a for hereditary hemorrhagic telangiectasia (HHT). The company reported $227.1M in cash at June 30, 2026, projected to fund operations into Q1 2029.